Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | IDH1 R132H IDH1 T313I |
| Therapy | Ivosidenib |
| Indication/Tumor Type | leukemia |
| Response Type | resistant |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| IDH1 R132H IDH1 T313I | leukemia | resistant | Ivosidenib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Tibsovo (ivosidenib) did not inhibit Idh1 activity and R-2HG production in a leukemia cell line expressing IDH1 R132H and T313I in culture and did not reduce tumor burden in a cell line xenograft model (PMID: 36222845). | 36222845 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (36222845) | Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance. | Full reference... |